Allogene Therapeutics

Please join Stanford oncologist Ash Alizadeh's presentation at #ASH2024, where he will provide an in-depth overview of the #ALPHA3 trial conducted by Allogene Therapeutics. The ALPHA3 trial is exploring the use of novel “off-she-shelf” (or allogeneic) #CART for first-line consolidation therapy in large B-cell lymphoma (#LBCL). The trial utilizes an investigational ultra-sensitive minimal residual disease (#MRD) detection by Foresight CLARITY? to identify MRD-positive patients for enrollment. We will examine how integrating cutting-edge diagnostics with next-generation, off-the-shelf CAR T therapies could transform current treatment approaches, expedite CAR T access—especially in community settings—and ultimately enhance cure rates for LBCL. This event is open to all ASH registrants. Add to calendar -> https://t.ly/1z5sa

We are looking forward to participating in the upcoming Piper Sandler and Citizens JMP investor conferences. Tune into our fireside chats to hear why we believe in the future of AlloCAR T products. Webcasts will be available in the IR section of our website. #CART #Immunotherapy https://lnkd.in/gSBb_Rvd

We look forward to presenting pre-clinical data on ALLO-329, our investigational allogeneic CAR T, at #ACR24 as we work to extend our pipeline innovation into autoimmune diseases. #CART #immunology #rheumatology https://lnkd.in/g8YVP5MM

Pleased to report our Q3 2024 corporate update and business highlights. https://lnkd.in/gtHcjrPx

New findings from the Phase 1 TRAVERSE trial evaluating an allogeneic CAR T in advanced #RCC reinforce the potential of this approach. Discover more about these promising data here, or join us at the Kidney Cancer Association's IKCS and the Society for Immunotherapy of Cancer (SITC) annual meeting to learn more. #CART https://lnkd.in/g_kkG2_4

We are looking forward to presenting new ALLO-316 data at the Society for Immunotherapy of Cancer (SITC) and Kidney Cancer Association IKCS annual meetings demonstrating the potential of our allogeneic #CART to address the unmet medical need for adults with advanced or metastatic CD70 positive RCC who have failed standard therapies.?#immunotherapy?https://lnkd.in/g4Tw9hVE

We are looking forward to participating in the upcoming Jefferies and Stifel Bank investor conferences. Tune into our fireside chats to hear why we believe in the future of AlloCAR T products. Webcasts will be available in the IR section of our website. #CART #Immunotherapy?https://lnkd.in/grHg5cjG

Join us for our Q3 conference call on Thursday, November 7th at 2:00 p.m. PT / 5:00 p.m. ET. A webcast will be available on the investor section of our website. https://lnkd.in/gnMDfe5F

Today we are pleased to announce the?FDA?granted Regenerative Medicine Advanced Therapy (RMAT) designation to ALLO-316 for the treatment of adults with CD70 positive advanced or metastatic #RCC. #CART #Immunotherapy https://lnkd.in/ghUMdXiV

Learn how our experience and differentiated science is enabling us to design and develop a #CART 2.0 product for autoimmune disease that is scalable and could eliminate or reduce lymphodepletion?to meet the unique needs of patients. #celltherapy #immunotherapy ? Uncover the Potential of ALLO-329:?Allogene.com/Pipeline